Target amount of €5.33 million Subscription price: €1.22 per share Subscription ratio: 1 new share for every 2 existing shares Subscription period: November 3, 2021 to November 18, 2021 inclusive Detachment of preferential subscription…
Theradiag close to breakeven Thanks to a sharp improvement in the net result before non-recuring items: +84.3% While maintaining its R&D and US investment strategy to fuel future growth Theradiag will hold a videoconference…
Click on the image below to find the interview with Bertrand de Castelnau, CEO of Theradiag, who presents the main assets of the company, the major events of H1 2021 and Theradiag's medium-term objectives: Or click on…